From the clinical and biological features of AML (age at diagnosis over 65 years, ELN high-risk and intermediate-risk, presence of FLT3 and DNMT3A mutations, ECOG performance status ≥ 2, WBC count ≥ 10,000 cells/mm3, LDH level ≥ 600 IU/L, associated with a poor OS), only LDH level ≥ 600 IU/L was associated with an increased hazard of death, and this association remained significant when quantifying for effect modification by FLT3 (ITD, D835) mutation status. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.